Eli Lilly And Co vs DENTSPLY SIRONA Inc — how do they compare? Eli Lilly And Co trades at $1,224.85 (market cap $1.08T), while DENTSPLY SIRONA Inc trades at $11.23 (market cap $2.31B). The key difference: Eli Lilly And Co is far larger — about 467.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| LLY | XRAY | |
|---|---|---|
Market Cap | $1.08T | $2.31B |
Sector | Health | Health |
52-Week High | $1.24K | $14.68 |
52-Week Low | $639.43 | $9.64 |
Enterprise Value | $1.13T | $4.39B |
Dividend Yield | 0.57% | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
DENTSPLY SIRONA (XRAY) trades at $11.66, down 3.8% on the day, with a bearish technical outlook and mixed fundamentals. The stock faces headwinds from declining revenue and negative profitability, though Q2 2026 earnings beat expectations. Recent news highlights institutional stake increases and ongoing turnaround efforts amid weak dental market conditions.
The outlook remains challenging with persistent net losses and high debt, but cost controls and strategic partnerships offer potential stabilization. Risks include competitive pressures and macroeconomic softness, while analyst consensus is Hold with a $11.50 price target, suggesting limited near-term upside.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →